<?xml version='1.0' encoding='utf-8'?>
<document id="31845095"><sentence text="The Risk of QTc-Interval Prolongation in Breast Cancer Patients Treated with Tamoxifen in Combination with Serotonin Reuptake Inhibitors."><entity charOffset="77-86" id="DDI-PubMed.31845095.s1.e0" text="Tamoxifen" /><entity charOffset="107-116" id="DDI-PubMed.31845095.s1.e1" text="Serotonin" /><pair ddi="false" e1="DDI-PubMed.31845095.s1.e0" e2="DDI-PubMed.31845095.s1.e0" /><pair ddi="false" e1="DDI-PubMed.31845095.s1.e0" e2="DDI-PubMed.31845095.s1.e1" /></sentence><sentence text="Antidepressants like the serotonin reuptake inhibitors (SRIs) are often used concomitantly with tamoxifen (e"><entity charOffset="25-34" id="DDI-PubMed.31845095.s2.e0" text="serotonin" /><entity charOffset="96-105" id="DDI-PubMed.31845095.s2.e1" text="tamoxifen" /><pair ddi="false" e1="DDI-PubMed.31845095.s2.e0" e2="DDI-PubMed.31845095.s2.e0" /><pair ddi="false" e1="DDI-PubMed.31845095.s2.e0" e2="DDI-PubMed.31845095.s2.e1" /></sentence><sentence text="g" /><sentence text=" for treatment of depression)" /><sentence text=" This may lead to an additional prolongation of the QTc-interval, with an increased risk of cardiac side effects" /><sentence text=" Therefore we investigated whether there is a drug-drug interaction between tamoxifen and SRIs resulting in a prolonged QTc-interval"><entity charOffset="76-85" id="DDI-PubMed.31845095.s6.e0" text="tamoxifen" /></sentence><sentence text="" /><sentence text="Electrocardiograms (ECGs) of 100 patients were collected at steady state tamoxifen treatment, with or without concomitant SRI co-medication"><entity charOffset="73-82" id="DDI-PubMed.31845095.s8.e0" text="tamoxifen" /></sentence><sentence text=" QTc-interval was manually measured and calculated using the Fridericia formula" /><sentence text=" Primary outcome was difference in QTc-interval between tamoxifen monotherapy and tamoxifen concomitantly with an SRI"><entity charOffset="56-65" id="DDI-PubMed.31845095.s10.e0" text="tamoxifen" /><entity charOffset="82-91" id="DDI-PubMed.31845095.s10.e1" text="tamoxifen" /><pair ddi="false" e1="DDI-PubMed.31845095.s10.e0" e2="DDI-PubMed.31845095.s10.e0" /><pair ddi="false" e1="DDI-PubMed.31845095.s10.e0" e2="DDI-PubMed.31845095.s10.e1" /></sentence><sentence text="" /><sentence text="The mean QTc-interval was 12" /><sentence text="4 ms longer when tamoxifen was given concomitantly with an SRI (95% CI:1"><entity charOffset="17-26" id="DDI-PubMed.31845095.s13.e0" text="tamoxifen" /></sentence><sentence text="8-23" /><sentence text="1 ms; P = 0" /><sentence text="023)" /><sentence text=" Prolongation of the QTc-interval was particularly pronounced for paroxetine (17"><entity charOffset="66-76" id="DDI-PubMed.31845095.s17.e0" text="paroxetine" /></sentence><sentence text="2 ms; 95%CI:1" /><sentence text="4-33" /><sentence text="0 ms; P = 0" /><sentence text="04), escitalopram (12" /><sentence text="5 ms; 95%CI:4" /><sentence text="4-20" /><sentence text="6 ms; P &lt; 0" /><sentence text="01) and citalopram (20"><entity charOffset="8-18" id="DDI-PubMed.31845095.s25.e0" text="citalopram" /></sentence><sentence text="7 ms; 95%CI:0" /><sentence text="7-40" /><sentence text="7 ms; P = 0" /><sentence text="047), where other agents like venlafaxine did not seem to prolong the QTc-interval"><entity charOffset="30-41" id="DDI-PubMed.31845095.s29.e0" text="venlafaxine" /></sentence><sentence text=" None of the patients had a QTc-interval of &gt;500 ms" /><sentence text="" /><sentence text="Concomitant use of tamoxifen and SRIs resulted in a significantly higher mean QTc-interval, which was especially the case for paroxetine, escitalopram and citalopram"><entity charOffset="19-28" id="DDI-PubMed.31845095.s32.e0" text="tamoxifen" /><entity charOffset="126-136" id="DDI-PubMed.31845095.s32.e1" text="paroxetine" /><entity charOffset="138-150" id="DDI-PubMed.31845095.s32.e2" text="escitalopram" /><entity charOffset="155-165" id="DDI-PubMed.31845095.s32.e3" text="citalopram" /><pair ddi="false" e1="DDI-PubMed.31845095.s32.e0" e2="DDI-PubMed.31845095.s32.e0" /><pair ddi="false" e1="DDI-PubMed.31845095.s32.e0" e2="DDI-PubMed.31845095.s32.e1" /><pair ddi="false" e1="DDI-PubMed.31845095.s32.e0" e2="DDI-PubMed.31845095.s32.e2" /><pair ddi="false" e1="DDI-PubMed.31845095.s32.e0" e2="DDI-PubMed.31845095.s32.e3" /><pair ddi="false" e1="DDI-PubMed.31845095.s32.e1" e2="DDI-PubMed.31845095.s32.e1" /><pair ddi="false" e1="DDI-PubMed.31845095.s32.e1" e2="DDI-PubMed.31845095.s32.e2" /><pair ddi="false" e1="DDI-PubMed.31845095.s32.e1" e2="DDI-PubMed.31845095.s32.e3" /><pair ddi="false" e1="DDI-PubMed.31845095.s32.e2" e2="DDI-PubMed.31845095.s32.e2" /><pair ddi="false" e1="DDI-PubMed.31845095.s32.e2" e2="DDI-PubMed.31845095.s32.e3" /></sentence><sentence text=" When concomitant administration with an SRI is warranted venlafaxine is preferred"><entity charOffset="58-69" id="DDI-PubMed.31845095.s33.e0" text="venlafaxine" /></sentence><sentence text="" /></document>